Kyntra Bio, Inc. expected to post a loss of $3.18 a share - Earnings Preview

Kyntra Bio

11/08/2026 21:43

Kyntra Bio, Inc. KYNB.OQ KYNB.O is expected to  show a rise in quarterly revenue when it reports  results on August 13 for the period ending June 30 2026
The San Francisco California-based  company is expected to report a 48.9% increase in revenue to $2.007 million from $1.35 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Kyntra Bio, Inc. is for a loss of $3.18 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Kyntra Bio, Inc. is $39.00, about 459.5% above its last closing price of $6.97
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-3.28
-3.35
-3.76
Missed
-12.1
Dec. 31 2026
-3.88
-3.61
Beat
7.1
Sep. 30 2025
-4.19
-4.00
-3.25
Beat
18.9​
Jun. 30 2025
-2.63
-2.30
-1.88
Beat
18.4
​​Mar. 31 2025
0.50
0.50
1.25
Beat
150
Dec. 31 2024
-2.00
-3.50
4.50
Beat
228.6​
Sep. 30 2024
-7.74
-7.62
-4.25
Beat
44.3
Jun. 30 2024
-8.71
-8.00
-4.00
Beat
50
This summary was machine generated August 11 at 20:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)